Genmab — Oktober 2020
-
"we and Genmab recently amended specifics of the TV global commercialization plan, whereby Seagen will lead global commercial activities, except in Japan. We will continue joint decision-making on worldwide strategy and Seagen and Genmab will co-promote TV in the U.S. In addition, Seagen will lead the majority of global operational development activities.
-
We and Genmab plan to submit the BLA to the FDA to support accelerated approval in this indication and to initiate a randomized confirmative trial of TV and cervical cancer in the coming months. We are also advancing clinical trials of TV monotherapy in other cancers and in combination with other agents.
-
And so when we come in with our data it's the best data that we've seen in this type of patient population of relapse, cervical cancer. [] And so I look at this and say, wow, if we can have these data, single-agent what could we do if we combine it with a checkpoint or any of these other agents? "
-
@pensionisten, man kan også vende den og sige, at hvis ikke det var for alle de gode nyheder, hvor langt var vi så nede nu
-
Thanks E L. Looks like we will have 2 more Genmab developed products on the market next year. Tiso and Amivatamab. That’s a total of 5 then. 1 year ago it was only dara (Arzerra hardly contributed with revenues). Fantastic development...:-)
-
Agree, I am really looking forward to those presentations...
-
Ja, men ADC betaler alle udgifter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind